OCREVUS

उत्पाद अवलोकन

About OCREVUS

OCREVUS is a prescription medication used to treat two forms of multiple sclerosis (MS): relapsing forms of MS and primary progressive MS. It contains the active ingredient Ocrelizumab, a humanized monoclonal antibody that targets CD20-positive B cells.

Key Benefits & Uses

• Treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS
• Treatment of primary progressive MS

Active Ingredient & Action

OCREVUS works by selectively targeting and depleting CD20-positive B cells, which are believed to play a role in the pathogenesis of MS. By reducing the number of B cells in the body, OCREVUS may help to slow disease progression and reduce the frequency of relapses.

Important Notes

OCREVUS is administered via intravenous infusion every 6 months. It is essential to follow the recommended dosing schedule and to report any adverse reactions or concerns to your healthcare provider. As with any medication, OCREVUS may cause side effects, including infusion reactions, upper respiratory tract infections, and skin reactions. Consult your healthcare provider for more information on the safe use of OCREVUS.